INTRODUCTION

Laboratory medicine as a medical discipline plays an indispensable role in predicting disease susceptibility, establishing effective preventive measures, enabling early-stage diagnoses, predicting and monitoring disease, and improving patient-centered care for better prognosis.\(^1\) Evaluation of clinical experimental performance is an important prerequisite for ensuring the quality of measurements.\(^4\) The "All Common Checklist" of the College of American Pathologists Accreditation Program stipulates that *for quantitative tests, the
laboratory must verify or establish the method performance specifications that are applicable and clinically relevant.\textsuperscript{5} At present, the general performance evaluation indexes include the limit of detection (LoD), accuracy, precision, and linear evaluation.\textsuperscript{6,7} However, there is no relevant index that reflects the minimum measurement difference within a certain concentration range. In many cases, the LoD is used to reflect the sensitivity of a detection system. The LoD refers to the smallest concentration that can be reliably measured by an analytical procedure, which can distinguish 0 from the minimum detection concentration but cannot specify the minimum detectable measurement within a certain concentration range.\textsuperscript{8,9} Reflecting this experimental minimum within the concentration range is an important performance evaluation index, which is related to, yet different from the LoD. However, at present, there is no relevant evaluation index. Therefore, we introduced the concept of “experimental resolution” to address this issue, with the aim of improving the experimental performance evaluation. The experimental resolution is the minimum change that can be detected by an instrument, which should be the basis of the LoD.\textsuperscript{10} Thus, the experimental resolution and LoD are related but separate parameters. As the future of medicine is based on effective patient-centered practice, it is therefore important to select test items with appropriate experimental resolution according to the clinical needs.\textsuperscript{11}

Clinical experiments can be divided into quantitative, semi-quantitative, and qualitative assays.\textsuperscript{4} The higher the experimental resolution, the better the quantitative effect. Experimental resolution is the key index for evaluating test performance, but no research has been done on a measurement method for experimental resolution or its related data to evaluate test performance.

To address these issues, this study adopted a method involving an equal-proportion dilution series of samples and used the improved linear measurement method to measure the experimental resolution of commonly used assays, including clinical biochemical, automatic hematology analyzer, chemical, immunological, and qPCR assays. By analyzing the test results, we found that the experimental resolution of the clinical biochemical experiments and the automatic hematology analyzer experiments were generally higher than 10% but remained lower than traditional chemical experiments (for which the experimental resolution could reach 1%). Surprisingly, the experimental resolution of the immunoassay and real-time fluorescence quantitative assay, which are generally considered to be more sensitive methods, was lower than 1%.\textsuperscript{12-14} By analyzing Pearson’s correlation of the correlation coefficients of the results of biochemical samples with different concentration gradients, the results of samples with different dilution ratios could not be predicted, and the experimental resolution should therefore be based on actual measurements rather than relying on a single dilution series. Thus, we propose that the experimental resolution is an important index for the evaluation of experimental performance.

2 | MATERIALS AND METHODS

2.1 | Preparation of equal-proportion dilution samples

For the preparation of samples with a 50% concentration gradient of equal-proportion dilutions, 200 µl normal saline was placed in each Eppendorf (EP) tube, and 200 µl serum was added to the first tube. After thorough mixing, 200 µl diluted sample was taken from the first tube and added to the second tube, which was thoroughly mixed. This was followed by two similar dilutions. Serially diluted samples with relative concentrations of 1000% (undiluted serum), 500%, 250%, 125%, and 62.5% were obtained.

For the preparation of samples with a 25% concentration gradient of equal-proportion dilutions, 200 µl normal saline was placed in each EP tube, and 600 µl serum was added to the first tube. After thorough mixing, 600 µl diluted sample was taken from the first tube and added to the second tube, which was thoroughly mixed. This was followed by two similar dilutions. A series of diluted samples with relative concentrations of 1000% (undiluted serum), 750%, 563%, 422%, and 316% were obtained.

For the preparation of samples with a 10% concentration gradient of equal-proportion dilutions, 160, 80, 40, and 20 µl normal saline were placed in each of the four EP tubes, respectively, and 1440 µl serum was added to the first tube. After thorough mixing, 720 µl diluted sample was taken from the first tube and added to the second tube, which was thoroughly mixed. Then, 360 µl diluted sample was taken from the second tube and added to the third tube, which was thoroughly mixed. Finally, 180 µl diluted sample was taken from the third tube and added to the fourth tube and thoroughly mixed to obtain a series of diluted samples with relative concentrations of 1000% (undiluted serum), 900%, 810%, 729%, and 656%.

For the preparation of samples with a 1% concentration gradient of equal-proportion dilutions, 0.4, 0.2, 0.1, and 0.05 ml normal saline were placed in each of four beakers, respectively, and 39.6 ml serum was accurately measured with an acid burette into the first beaker. After fully mixing, 19.8 ml diluted sample was accurately measured from the first beaker into the second beaker and fully mixed. Then, 9.9 ml diluted sample was taken from the second beaker into the third beaker and thoroughly mixed. Finally, 4.95 ml diluted sample was taken from the third beaker into the fourth beaker and thoroughly mixed to obtain a series of diluted samples with relative concentrations of 1,000% (undiluted serum), 990%, 980%, 970%, and 961%, as shown in Figure 1.

After each serum sample was diluted, albumin (ALB) was measured. If the ALB test results of the diluted samples showed good linearity (p ≤ 0.01) with the relative concentration, this the dilution was considered accurate, and the sample could be used for subsequent analysis.
2.2 | Determination of the experimental resolution of biochemical tests, automatic hematology analyzer methods, immunoassays, chemical experiments, and qPCR

2.2.1 | Biochemical tests

In total, 15 items, including glutamic-oxalacetic transaminase (AST), glutamic-alanine transaminase (ALT), total bilirubin (TBil), direct bilirubin (DBil), total protein (TP), albumin (ALB), creatinine (CREA), uric acid (UA), urea (UR), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), lactate dehydrogenase (LDH), and glucose (Glu) in the diluted serum samples, were detected using a Mindray BS-800 M automatic biochemical analyzer (Shenzhen Mindray Biomedical Electronics Co., Ltd).

2.2.2 | Automatic hematology analyzer method

The Mindray BC-6000 automatic hematology analyzer (Shenzhen Mindray Biomedical Electronics Co., Ltd.) was used to detect nine items, including white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hb), and platelets (PLT), in the diluted blood samples.

2.2.3 | Enzyme-linked immunosorbent assay

Serially diluted positive serum samples of anti-HBV surface antigen (anti-HBs) were detected using an anti-HBs commercial ELISA kit (Shenyang Huimin Biological Technology Co., Ltd) according to the manufacturer’s instructions.

2.2.4 | Colloidal gold method

The HCG test card was used to detect the HCG-positive series of diluted urine samples, and the reaction results were photographed and processed. Image J v1.8.0 was used to process the photographs to obtain the gray scale of the C area of the quality control line and the T area of the test line. The gray scale ratio (T/C) between the test line and quality control line was calculated using the following formula:

\[ \frac{T}{C} = \frac{\text{the gray scale of the C area}}{\text{the gray scale of the T area}} \]

2.2.5 | Chemiluminescence immunoassay

The concentration of carcinoembryonic antigen in the diluted samples was determined using a Mindray i2000 chemiluminescence analyzer (Shenzhen Mindray Biomedical Electronics Co., Ltd.).

2.2.6 | Gas chromatography experiments

A series of diluted toluene and benzene samples were detected by GC-7860 gas chromatography (Shanghai Appropriate Electronic Technology Co., Ltd). The reaction conditions were as follows. The hydrogen pressure in the gas chromatography column was maintained at 0.1 MPa. The chromatographic experimental conditions included a chromatographic column temperature of 80°C, a gasification chamber temperature of 150°C, and a detector temperature of 200°C. Diluted samples of different concentrations were detected, and their complete chromatograms and retention times were recorded. The toluene and benzene contents were calculated as follows:

\[ A_i\% = \frac{A_i f_{mi}}{\sum A_i f_{mi}} \times 100\% \]

where \( A_i \) = the peak area of component i, \( f_{mi} \) = the relative correction factor of component i, and the relative correction factors of benzene and toluene were 0.89 and 0.94, respectively.

2.2.7 | Flame atomic absorption spectrophotometry

The absorbance values of the copper and strontium diluted samples were determined using an SP-3900AA flame atomic absorption spectrometer (Shanghai Spectrum Instruments Co., Ltd.).
2.2.8 | qPCR

TransStart Top Green qPCR Supermix (TransGen Biotech Co., Ltd) and diluted DNA samples were used to construct a qPCR system for the amplification of genes (ie, the 18S ribosomal RNA gene), and the relative DNA concentration N was calculated as follows:

\[ N = 2^{(C_{\text{t}}-C_{\text{t}})} \]  

(3)

where \( C_{\text{t}} \) is the Ct value of the undiluted sample and Ct is the Ct value of the treated sample.

2.3 | Establishment of an experimental resolution method

The linear evaluation method was used to evaluate the experimental resolution. The specific method has been previously reported in the literature,\textsuperscript{15} with some modifications:

1. The equal-proportion concentration gradient dilution method was adopted instead of the equal-spacing concentration gradient dilution method for the linear evaluation of the diluted samples.
2. In the original method, the same sample was measured at least twice in parallel. For the purposes of this study, to control the detection range, the same sample was designed to be tested only once.
3. According to the definition of experimental resolution, linear regression was used to analyze the experimental results, with the relative concentration used as the independent variable and the actual test value as the dependent variable for linear fitting. When determining the boundary value, the \( p \)-value was reduced from 0.05 to 0.01.

Therefore, the modified experimental resolution determination method was as follows: the correlation analysis was conducted between the actual measured values obtained from each experiment and the relative concentration. It was stipulated that the fitting result was valid for \( p \leq 0.01 \) and invalid for \( p > 0.01 \). If the fitting result between the detection results and the relative concentration was still valid for the detection of the 50% concentration gradient dilution series samples, then the experimental resolution was 50%—indicating a qualitative experiment; if the fitting result between the detection results and the relative concentration was still valid for the measurement of the 25% concentration gradient dilution series samples, then the experimental resolution was 25%—indicating a semi-quantitative experiment; and if the fitting result between the detection results and the relative concentration was still valid for the measurement of the 10% concentration gradient dilution series samples, then the experimental resolution was 10%—indicating a quantitative experiment. Using urea as an example, the \( p \)-value of the correlation analysis results between the detection results of the samples with an equal dilution of 50%, 25%, and 10% concentration gradients and the relative concentration <0.01, and the \( p \)-value of the correlation analysis results between the detection results of samples with equal dilution of a 1% concentration gradient and the relative concentration >0.01, as shown in Figures 2 and 3. The fitting results between the results of the samples diluted in equal proportions up to the 10% concentration gradient and the relative concentration were effective. Therefore, the experimental resolution of urea detection was 10%, which was a quantitative experiment.

3 | RESULTS

The correlation between the detection results of common clinical biochemical indicators of sera with concentration gradients of 25%, 10%, and 1% with the relative concentrations is shown in Table 1. The results showed a significant \( p \leq 0.01 \) for the correlation test results between the detection results of all items (ALT, AST, TB, DB, TP, ALB, CREA, UA, UREA, TC, TG, HDL, LDL, LDH, Glu) in the samples with a concentration gradient dilution of 25% and the relative concentrations. Except for direct bilirubin (\( p = 0.013 \)), which was greater than the threshold value of 0.01, the correlation test results were significant between all results for the 10% concentration gradient dilution samples, and the relative concentrations (\( p \leq 0.01 \)). For the 1% concentration gradient dilution, only TP, ALB, and UA were significant (\( p \leq 0.01 \) for all).

The detection results for the experimental resolution of the automatic hematology analyzer are presented in Table S1. The experimental resolutions of BAS and MON could only reach 50% and 25%, respectively. Anticoagulant blood was tested with a 10% concentration gradient dilution, and the test results showed that the \( p \)-values of WBC, NEU, LYM, EOS, RBC, Hb, and PLT were all within the effective range. In the 1% concentration gradient dilution samples, only the test results for RBC were significant (\( p < 0.01 \)). To judge whether the dilution of a 1% concentration gradient of the anticoagulant was accurate, we used a biochemical method for verification. The results showed that the correlation analysis between the ALB test results, and the relative concentration were significant (\( p < 0.01 \)), which confirmed it as a qualified sample for dilution.

The experimental resolution of the manual immunoassay could only reach 25%, not 10%, while the experimental resolution of the automated immunoassay (chemiluminescence immunoassay) could reach 1%, as shown in Table 2. The experimental resolution detection results of gas chromatography and flame atomic absorption spectrophotometry are shown in Table S2. The results showed that the experimental resolution of both methods reached 1%. The detection results showed that the experimental resolution of qPCR only reached 10%, which was not consistent with the commonly believed high sensitivity, as shown in Table 2.

Pearson’s correlation was calculated for the correlation coefficients of the biochemical results of samples with different concentration gradient dilutions. No correlation was detected between the
results of the samples with 25%, 10%, and 1% concentration gradient dilutions, as shown in Table 3.

4 | DISCUSSION

The experimental resolution refers to the minimum variation that can be detected by an instrument. We believe that the magnitude of the minimum variation can be explained by the merits and demerits of linear fitting. Although imprecision errors or matrix effects can reflect the precision and accuracy of assays, the poor performance of any of the above indicators will affect the experimental resolution.

Therefore, the experimental resolution can comprehensively reflect imprecision errors, matrix effects, linearity errors, and other indicators. The experimental resolution is a more intuitive and direct indicator of the advantages and disadvantages of assays compared to the above-mentioned indicators. In clinical practice, specimens are usually tested only once; therefore, experimental resolution advocates that a concentration should also be tested only once, which can be a more rigorous assessment of the experiment, and more in line with clinical practice.

The evaluation of linearity usually adopts the equal-spacing dilution method to dilute samples, such as a group of equal-spacing dilution samples with concentrations of 100, 80, 60, 40, and
20 mmol/L. However, the problem with this method is the degree of change between the sample concentrations before and after dilution. For example, when considering a difference of 25 mmol/L between samples, the concentration changed by 30% when a 75 mmol/L sample was diluted to 50 mmol/L, whereas the concentration changed by 50% when a 50 mmol/L sample was diluted to...
TABLE 2

| 10% | 1% |
|-----|----|
| **Relative concentration** | **Measured value** | **R (P)** | **Relative concentration** | **Measured value** | **R (P)** |
| 1000% | 0.989 | 0.854 (0.065) | 1000% | 32.870 | 0.959 (0.010) |
| 900%  | 0.284 | – | 900%  | 31.110 | – |
| 810%  | 0.091 | – | 810%  | 31.150 | – |
| 729%  | 0.069 | – | 729%  | 29.620 | – |
| 656%  | 0.067 | – | 656%  | 29.250 | – |
| 1000% | 1.513 | 0.948 (0.014) | 1000% | – | – |
| 900%  | 1.201 | – | 900%  | – | – |
| 810%  | 1.173 | – | 810%  | – | – |
| 729%  | 1.040 | – | 729%  | – | – |
| 656%  | 0.994 | – | 656%  | – | – |

| 10% | 1% |
|-----|----|
| **Relative concentration** | **Measured value** | **R (P)** | **Relative concentration** | **Measured value** | **R (P)** |
| 1000% | 48.460 | 0.958 (0.010) | 1000% | 1.000 | 0.996 (<0.001) |
| 900%  | 48.680 | 990% | 30.070 | 0.974 (0.038) |
| 810%  | 44.650 | 980% | 30.000 | 0.974 (0.038) |
| 729%  | 42.000 | 970% | 29.620 | 0.974 (0.038) |
| 656%  | 39.100 | 961% | 29.250 | 0.974 (0.038) |
| 1000% | 1.000 | 1000% | 1.000 | 0.224 (0.717) |
| 900%  | 0.774 | 990% | 0.774 | – |
| 810%  | 0.607 | 980% | 0.633 | – |
| 729%  | 0.493 | 970% | 0.763 | – |
| 656%  | 0.361 | 961% | 0.908 | – |

25 mmol/L; therefore, the equal-proportion dilution method must be used. Unlike testing the linearity of an experiment using a single concentration gradient dilution sample, we designed an experiment using the equal-proportion dilution method, which ensured that the concentration of each point in the dilution process changed to the same degree, so that the experimental resolution could be
The results showed that the experimental resolution of assaying direct bilirubin only reached 25%, indicating that this assay could only be used for semi-quantitative analysis, whereas the experimental resolution of the other biochemical experiments, including ALT, AST, TB, ALB, CREA, UA, UREA, TC, TG, HDL, LDL, LDH, and Glu, all reached 10%, indicating that these assays could be used for quantitative analysis. Among them, the experimental resolution of TP, ALB, and UA reached 1%, indicating that they could be used for more accurate measurements. As for blood cell counts, the experimental resolution of macrophage detection was only 25%, and that of basophil detection only 50%, due to the small number of macrophages and basophils. The experimental resolution of other assays, such as WBC, NEU, LYM, EOS, HB, and PLT, reached 10%, indicating that they could be quantitatively detected, while the experimental resolution of RBC detection reached 1% and is therefore a more accurate assay. It is generally believed that the sensitivity of immune experiments is high, but we found that the experimental resolution of manual immune experiments only reached 25%—not 10%. Therefore, manual immune experiments only achieved semi-quantitative analysis, while automated immune experiments reached 1%, allowing for quantitative analysis. The biochemical experiment was based on a chemical assay, but it achieved a better experimental effect. Therefore, we further explored the classical chemical experiments. The results showed that the experimental resolution of both gas chromatography and flame atomic absorption spectrophotometry reached 1%, indicating that classical chemical methods remain effective methods of measurement. The results showed that the experimental resolution of qPCR was 10%—not 1%, which was contrary to the high sensitivity usually associated with this method. By calculating Pearson’s correlation of the correlation coefficients for the biochemical results of samples with different concentration gradients, we found no mutual prediction effect between the results of different dilution series, and the experimental resolution should therefore be based on the actual measurement. Furthermore, it was not possible to use only one dilution series to predict higher experimental resolution results (see Table 3). In addition, for the fitting curve, we only considered whether the fitting result met the requirement of \( p \leq 0.01 \) and did not consider the slope or intercept of the fitting curve. If the fitting effect is good, the accuracy can be further improved by regression.

In conclusion, the established determination method for experimental resolution effectively detected the experimental resolution of various clinical experiments and can be used to evaluate whether biochemical methods, automatic hematology analyzer methods, immunoassay methods, chemical methods, and qPCR are qualitative, semi-quantitative, or quantitative experiments, which have significant implications for the evaluation of clinical trial performance. Therefore, the experimental resolution may be considered as a new index for the performance evaluation of clinical trials, which will influence new discoveries resulting from biochemical tests, complete blood count tests, chemical experiments, immunoassays, qPCR, and other medical tests.

**CONFLICT OF INTEREST**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this study.

**AUTHOR CONTRIBUTIONS**

Hui Liu and Chenxi Sun designed the experiments. Chenxi Sun and Dongxia Wang performed the experiments. Chenxi Sun analyzed the data and wrote the study. Hui Liu reviewed and edited the study. Henggui Xu, Guang Yang, and Xiaomei Yan provided study materials. All authors have read and approved the final study and take responsibility for its integrity.
DATA AVAILABILITY STATEMENT
All relevant data are within the study, and no additional data are available.

ORCID
Hui Liu https://orcid.org/0000-0002-1262-1168

REFERENCES
1. Greaves RF, Bernardini S, Ferrari M, et al. Key questions about the future of laboratory medicine in the next decade of the 21st century: a report from the IFCC-emerging technologies division. Clin Chim Acta. 2019;495:570-589.
2. Plebani M, Lippi G. Improving diagnosis and reducing diagnostic errors: the next frontier of laboratory medicine. Clin Chem. 2016;54:1117-1118.
3. Gruson D, Bernardini S, Dabla PK, Gouget B, Stankovic S. Collaborative AI and laboratory medicine integration in precision cardiovascular medicine. Clin Chim Acta. 2020;509:67-71.
4. Pum J. A practical guide to validation and verification of analytical methods in the clinical laboratory. Adv Clin Chem. 2019;90:215-281.
5. College of American Pathologists CAP, Accreditation Program— All Common Checklist, 2015.
6. Sadler WA. Using the variance function to estimate limit of blank, limit of detection and their confidence intervals. Ann Clin Biochem. 2016;53(1):141-149.
7. Cao TH, Xu NJ, He M, Liu H. Comprehensive Evaluation and Clinical Application of Combined Redox Assay Methods to Determine Total Antioxidant Capacity. Curr Anal Chem. 2017;13(6):493-498.
8. Linnet K, Kondratovich M. Partly nonparametric approach for determining the limit of detection. Clin Chem. 2004;50(4):732-740.
9. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(suppl 1):549-552.
10. Li J, Zhou X, Zhang M, Zhang J, Qiao L. Temperature resolution improvement in raman-based fiber-optic distributed sensor using dynamic difference attenuation recognition. Sensors. 2020;1-18.
11. Hallworth MJ, Epner PL, Ebert C, et al. Current evidence and future perspectives on the effective practice of patient-centered laboratory medicine. Clin Chem. 2015;61:589-599.
12. Matope G, Muma JB, Toft N, et al. Evaluation of sensitivity and specificity of RBT, c-ELISA and fluorescence polarisation assay for diagnosis of brucellosis in cattle using latent class analysis. Vet Immunol Immunopathol. 2011;141:58-63.
13. Li X, Chen H, Wei J, Lv N, You L. The evaluation of colloidal gold immunochromatographic assay (GICA) for rapid diagnosis of influenza A disease. Clin Chem Lab Med. 2011;49:1533-1537.
14. Jääskeläinen AJ, Sironen T, Diagne CT, et al. Development, validation and clinical evaluation of a broad-range pan-filovirus RT-qPCR. J Clin Virol. 2019;114:26-31.
15. Krouwer JS, Schlain B. A method to quantify deviations from assay linearity [published correction appears in Clin Chem 1994 Sep;40(9):1781]. Clin Chem. 1993;39(8):1689-1693.
16. Nötz D, Frontzek A, Eigner U, et al. Pushing beyond specifications: Evaluation of linearity and clinical performance of the Cobas 6800/8800 SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations. J Clin Virol. 2020;132:1-7.
17. Killeen AA, Long T, Souers R, Styer P, Ventura CB, Klee GG. Verifying performance characteristics of quantitative analytical systems: Calibration verification, linearity, and analytical measurement range. Arch Pathol Lab Med. 2014;138:1173-1181.
18. Pum JKW. Evaluation of analytical performance of qualitative and semi-quantitative assays in the clinical laboratory. Clin Chim Acta. 2019;497:197-203.
19. Korstjens I, Moser A. Series: Practical guidance to qualitative research. Part 2: Context, research questions and designs. Eur J Gen Pract. 2017;23:274-279.
20. Nordin G. Before defining performance criteria we must agree on what a “qualitative test procedure” is. Clin Chem Lab Med. 2015;53:939-941.
21. Thaler MA, Bietenbeck A, Steigerwald U, et al. Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS One. 2019;14:1-17.
22. Coley NG. History of biochemistry. eLS. 2002;1-9.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Sun C, Wang D, Xu H, Yang G, Yan X, Liu H. A method for measuring the experimental resolution of laboratory assays (clinical biochemical, blood count, immunological, and qPCR) to evaluate analytical performance. J Clin Lab Anal. 2021;35:e24087. https://doi.org/10.1002/jcla.24087